VELTASSA maintained normokalemia through 1 year1
- Up to 95% of patients with hyperkalemia maintained normokalemia
- 100% of patients were on RAAS inhibitors at baseline
Normokalemia was defined as serum K+ within the target range of 3.8 to 5.0 mEq/L.
*Baseline serum K+>5.0 to 5.5 mEq/L.
†Baseline serum K+>5.5 to <6.0 mEq/L.
‡Dose strength studied, but not commercially available.
§Significant (P<0.001) increases in least squares mean serum K+ levels were seen by day 3 post-treatment.
*Significant (P<0.001) increases in least squares mean serum K+ levels were seen by day 3 post-treatment.
†Baseline serum K+>5.0 to 5.5 mEq/L.
‡Baseline serum K+>5.5 to <6.0 mEq/L.
§Dose strength studied, but not commercially available.
A phase 2, 52-week, multicenter, open-label, dose-ranging, randomized clinical trial in patients with CKD and type 2 diabetes mellitus taking RAAS inhibitors, consisting of an 8-week initiation phase and a 44-week maintenance phase. The primary efficacy endpoint was the mean change in serum K+ level from baseline to week 4 or prior to the initiation of dose titration.
VELTASSA was studied in patients like yours who are vulnerable to hyperkalemia1,2
In the OPAL-HK (12-week) and AMETHYST-DN (1-year) studies:
GUIDELINE- RECOMMENDED THERAPIES
100%of patients were receiving ACE inhibitors, ARBs, or other RAAS inhibitors
100% of patients had CKD, with the majority having type 2 diabetes mellitus
99% of patients had hypertension and up to 42% had heart failure